Celiac Disease Market Report 2026

The celiac disease market size has grown rapidly in recent years. It will grow from $0.78 billion in 2025 to $0.87 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to autoimmune disease awareness, improved diagnostics, dietary management adoption, hospital gastroenterology care, patient advocacy.

The celiac disease market size is expected to see strong growth in the next few years. It will grow to $1.27 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to novel drug development, gluten-free food innovation, personalized nutrition, early screening programs, microbiome research. Major trends in the forecast period include rising adoption of gluten-free diets, growth of packaged gluten-free foods, expansion of drug-based therapies, increased disease awareness and diagnosis, focus on microbiome-based treatments.

The growth of personalized medicine is expected to drive the expansion of the celiac disease market in the coming years. Personalized medicine is a healthcare approach that tailors medical care based on an individual’s genetic profile, environment, and lifestyle. The rising demand for personalized medicine is fueled by increased access to genetic testing, enabling more accurate diagnoses and targeted treatments customized for each patient. Personalized medicine supports celiac disease management by allowing precise identification of genetic markers and individual immune responses, leading to more effective and individualized treatment strategies. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the FDA authorized 16 personalized therapies in 2023 targeting rare diseases, up from 6 approvals in 2022. Therefore, the growth of personalized medicine is driving the celiac disease market.

Major companies in the celiac disease market are focusing on advanced therapies such as anti-interleukin-15 (IL-15) antibodies, designed to reduce tissue damage by modulating overactive immune cell activity. Anti-IL-15 antibodies are specialized proteins that inhibit IL-15, a cytokine involved in immune response, helping to control inflammation and immune-mediated tissue injury. For instance, in May 2025, Teva Pharmaceutical Industries, an Israel-based pharmaceutical company, announced that the U.S. Food and Drug Administration had granted Fast Track designation for TEV-53408, an investigational anti-IL-15 monoclonal antibody. This therapy is being developed for individuals with celiac disease who continue to experience symptoms despite adhering to a gluten-free diet. TEV-53408 functions by blocking IL-15, which plays a key role in triggering intestinal immune damage in celiac patients, and is currently undergoing Phase 2a clinical trials to evaluate its safety and efficacy.

In May 2025, Targeted Genomics, a US-based company specializing in celiac disease genetics and wellness, partnered with OraSure Technologies to offer direct-to-consumer (DTC) genetic testing for celiac disease. This collaboration allows Targeted Genomics to leverage OraSure’s expertise in diagnostics to provide individuals with personalized genetic risk information, enhancing proactive health management. OraSure Technologies is a US-based provider of celiac disease diagnostic solutions.

Major companies operating in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.

North America was the largest region in the celiac disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the celiac disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the celiac disease market by raising costs for gluten-free raw materials, specialty foods, diagnostic kits, and pharmaceutical treatments. Gluten-free food products and biologic drug segments are most affected, particularly in North America and Europe where cross-border food and healthcare trade is high. Homecare and hospital channels experience price pressure. However, tariffs are promoting domestic gluten-free food production and localized pharmaceutical manufacturing.

The celiac disease market research report is one of a series of new reports that provides celiac disease market statistics, including celiac disease industry global market size, regional shares, competitors with a celiac disease market share, detailed celiac disease market segments, market trends and opportunities, and any further data you may need to thrive in the celiac disease industry. This celiac disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Celiac disease is an autoimmune disorder in which the ingestion of gluten triggers immune-mediated damage to the small intestine, causing malabsorption and various symptoms. Diagnosis is typically made through blood tests and intestinal biopsy, and the primary treatment is a lifelong gluten-free diet to heal the intestine and prevent complications.

The main treatments for celiac disease include infliximab, larazotide acetate, gluten-free diets, and others. Infliximab is a monoclonal antibody that reduces inflammation by blocking tumor necrosis factor-alpha (TNF-α). It can be administered orally or parenterally and is used by end-users such as hospitals, home care providers, and others.

The celiac disease market consists of revenues earned by entities by providing services such as diagnostic testing services, histopathology services, dietary consultation, nutrition counseling, and food certification. The market value includes the value of related goods sold by the service provider or included within the service offering. The celiac disease market also includes sales of gluten-free foods, diagnostic test kits, nutritional supplements, gluten detection devices, and probiotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.